M Pharmaceutical in-Licenses Novel Pediatric Orphan Drug to Their Pipeline, with Possible Priority Review Voucher Award
M Pharmaceutical Inc., (the "Company" or "M Pharma"), a clinical-stage company developing innovative technologies for weight management and female health and wellness, today announced that it has in-licensed a novel drug product that should qualify as an Orphan Drug under the US Orphan Drug Act. This new drug and its orphan status should also qualify for a Rare Pediatric Disease designation and a Priority Review Voucher (PRV). PRV's are incentives designed by the FDA to spur the development on new...
View full press release